BTOG 2022 | Genomic testing for lung cancer in the UK

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, comments on the state of genomic testing non-small cell lung cancer (NSCLC). The Genomic Test Directory for Cancer implemented by Genomic Laboratory Hubs (GLHs) in England have enabled the detection of at least 8 genes via next-generation sequencing (NGS) of DNA and RNA. This allows patients to access targeted therapies and Prof. Popat highlights the need to be aware of the latest therapies that may be available via alternative licensing schemes such as Project Orbis. This interview took place at the 20th Annual British Thoracic Oncology Group (BTOG) Conference 2022.